OncoGenex's Apatorsen in Phase II Study - Analyst Blog

By
A A A

OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently announced the commencement of an investigator-sponsored phase II trial, Rainer, on its oncology candidate, apatorsen.

We note that OncoGenex is evaluating apatorsen (OGX-427) in combination with Celgene Corporation's ( CELG ) Abraxane and Gemzar in patients with previously untreated metastatic pancreatic cancer.

The randomized, placebo-controlled study will randomize 130 patients to receive either apatorsen or placebo in combination with Abraxane and Gemzar therapy. The primary end point is overall survival.

Other end points include progression-free survival (PFS), tumor response rates, safety, and tolerability among others.

OncoGenex estimates approximately 45,000 people will be diagnosed with pancreatic cancer in the U.S. leading to approximately 38,500 deaths in 2013. Hence, a positive result from the trial will be a significant step forward for OncoGenex to come up with a potential treatment option for pancreatic cancer.

Earlier in the month, OncoGenex initiated another phase II trial, Spruce, on apatorsen. OncoGenex is evaluating apatorsen for the treatment of previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

The trials are part of the ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program.

We remind investors that the most advanced candidate in OncoGenex's pipeline is custirsen (phase III) under evaluation for the treatment of metastatic castrate-resistant prostate cancer in men and also for the treatment of patients with advanced, unresectable non-small cell lung cancer.

OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd. ( TEVA ) to develop and commercialize the candidate.

The successful development and commercialization of custirsen will be a major positive for OncoGenex. OncoGenex currently has no approved drug in its portfolio. We expect investor focus to remain on custirsen.

OncoGenex currently carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals ( JAZZ ) looks attractive with a Zacks Rank #2 (Buy).



CELGENE CORP (CELG): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report


ONCOGENEX PHARM (OGXI): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: CELG , JAZZ , OGXI , PFS , TEVA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

45,543,019
  • $16.75 ▲ 0.12%
44,349,390
  • $132.54 ▲ 0.88%
32,695,176
  • $3.01 ▲ 19.92%
28,073,679
  • $34.76 ▲ 2.75%
27,339,999
  • $9.15 ▼ 3.58%
26,142,754
  • $34.71 ▼ 1.03%
25,357,890
  • $46.90 ▼ 1.10%
24,562,443
  • $15.27 ▼ 1.55%
As of 5/22/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com